Tudor Investment Corp’s AstraZeneca AZN Stock Holding History

Tudor Investment Corp’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-19,643	Closed	-$3.45M	–	3492
2025 Q3	$3.01M	Sell	19,643 -15,945	-45%	-$2.41M	0.01%	1531
2025 Q2	$4.97M	Buy	35,588 +17,950	+102%	+$2.52M	0.01%	1091
2025 Q1	$2.59M	Buy	17,638 +1,588	+10%	+$230K	0.01%	1163
2024 Q4	$2.1M	Buy	+16,050	New	+$2.25M	0.01%	1226
2023 Q4	–	Sell	-3,237	Closed	-$421K	–	2364
2023 Q3	$438K	Buy	+3,237	New	+$442K	﹤0.01%	1738
2023 Q1	–	Sell	-11,772	Closed	-$1.6M	–	2398
2022 Q4	$1.6M	Sell	11,772 -34,605	-75%	-$4.34M	0.03%	774
2022 Q3	$5.09M	Buy	+46,377	New	+$5.88M	0.11%	220
2014 Q3	–	Sell	-27,100	Closed	-$2.01M	–	1344
2014 Q2	$2.01M	Buy	+27,100	New	+$1.96M	0.08%	108

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Tudor Investment Corp's AZN Position: Q4 2025 in Review

Tudor Investment Corp sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 19,643 shares — an estimated $3.45M sold.

Tudor Investment Corp first reported a position in AZN in Q2 2014 and held it in 8 quarters. The position peaked at $5.09M in Q3 2022. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

Tudor Investment Corp reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
Tudor Investment Corp sold 19,643 AstraZeneca shares in Q4 2025, an estimated $3.45M.
Tudor Investment Corp first reported a position in AstraZeneca in Q2 2014 and held it in 8 quarters.
Tudor Investment Corp's AstraZeneca position peaked at $5.09M in Q3 2022.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.